SCHEMBL3942364

SCHEMBL3942364

COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(CCN(C)C)S(C)(=O)=O)c(F)c1)c1ccc2nccnc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 3/20 0.33
CASP1 P29466 2/20 0.32
MAPT P10636 5/20 0.32
KMT2A Q03164 4/20 0.32
SMN1; SMN2 Q16637 4/20 0.32
RAB9A P51151 3/20 0.32
NPC1 O15118 2/20 0.32
TP53 P04637 2/20 0.32
CTDSP1 Q9GZU7 1/20 0.32
MEN1 O00255 3/20 0.32
GAA P10253 2/20 0.31
POLB P06746 2/20 0.31
LMNA P02545 1/20 0.31
HTT P42858 1/20 0.31
FLT3 P36888 1/20 0.30
AURKB Q96GD4 1/20 0.30
MET P08581 1/20 0.30
AXL P30530 1/20 0.30
KDM4E B2RXH2 2/20 0.30
ALDH1A1 P00352 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5859759 1.00 ATM (0.33) ATMCASP1MAPTKMT2ASMN1; SMN2
SCHEMBL5856919 0.91 PDGFRB (0.32) ATMKMT2ARAB9ANPC1MEN1
SCHEMBL3933416 0.91 PDGFRB (0.32) ATMKMT2ARAB9ANPC1MEN1
SCHEMBL5859365 0.89 SMN1; SMN2 (0.39) ATMCASP1MAPTKMT2ASMN1; SMN2
SCHEMBL3933005 0.89 SMN1; SMN2 (0.39) ATMCASP1MAPTKMT2ASMN1; SMN2
SCHEMBL5856985 0.86 MAPK14 (0.34) CASP1MAPTKMT2ASMN1; SMN2RAB9A
SCHEMBL3945451 0.86 MAPK14 (0.34) CASP1MAPTKMT2ASMN1; SMN2RAB9A
SCHEMBL5857557 0.85 MAPT (0.35) ATMCASP1MAPTKMT2ASMN1; SMN2
SCHEMBL3944171 0.85 MAPT (0.35) ATMCASP1MAPTKMT2ASMN1; SMN2
SCHEMBL3935511 0.85 HPGD (0.40) MAPTKMT2ASMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1551830-B1 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA (DE) 2009-04-08 EP disclosed
US-7148249-B2 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-12-12 US disclosed
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments CDK1, CDK2, CDK3 ATM 678/4885CASP1 1119/4885MAPT 1798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.